Cystic Fibrosis Foundation

• NCT05788965

  Collaborator, Phase 2/3, Completed, 8 people, 29 Mar 2023

• NCT05704036

  Collaborator, Phase 4, Recruiting, 75 people, 30 Jan 2023

• NCT04310930

  Collaborator, Phase 2/3, Recruiting, 300 people, 17 Mar 2020

• NCT03206788

  Collaborator, Phase 2, Terminated, 7 people, 2 Jul 2017

• NCT03020719

  Collaborator, Phase 2, Completed, 60 people, 13 Jan 2017

• NCT02866721

  Collaborator, Phase 1, Completed, 14 people, 15 Aug 2016

• NCT01594827

  Collaborator, Phase 2, Completed, 29 people, 9 May 2012

• NCT01426256

  Collaborator, Phase 3, Completed, 91 people, 31 Aug 2011

• NCT00809094

  Collaborator, Phase 2, Completed, 70 people, 17 Dec 2008

• NCT00590538

  Collaborator, Phase 1/2, Terminated, 9 people, 10 Jan 2008

• NCT00016744

  Collaborator, Phase 1/2, Completed, 12 people, 4 Jun 2001

• Chemically modified CRISPR enzymes for multi-organ genome editing in vivo

  URNOV19XX0, 16 Sept 2026

Sources: api.crossref.org

• Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1

  Grants or research support, 2 Sept 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Pulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1

  Respiratory medicine, 3 Sept 2026